Nothing Special   »   [go: up one dir, main page]

AR041588A1 - Composicion farmaceutica estabilizada que comprende una sustancia activa amorfa - Google Patents

Composicion farmaceutica estabilizada que comprende una sustancia activa amorfa

Info

Publication number
AR041588A1
AR041588A1 ARP030103710A ARP030103710A AR041588A1 AR 041588 A1 AR041588 A1 AR 041588A1 AR P030103710 A ARP030103710 A AR P030103710A AR P030103710 A ARP030103710 A AR P030103710A AR 041588 A1 AR041588 A1 AR 041588A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
active substance
amorfa
amorphous
stabilized pharmaceutical
Prior art date
Application number
ARP030103710A
Other languages
English (en)
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32091984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR041588(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of AR041588A1 publication Critical patent/AR041588A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica que comprende la sustancia activa amorfa que es atorvastatin cálcico. Se describe el proceso de estabilización de la composición farmacéutica que comprende la formulación farmacéutica con atorvastatin cálcico amorfo, el proceso de estabilización de la formulación farmacéutica que comprende atorvastatin cálcico amorfo y el proceso de estabilización de atorvastatin cálcico en una forma amorfa. Reivindicación 1: Una composición farmacéutica estable que comprende una formulación farmacéutica con una substancia activa amorfa en la cual la formulación farmacéutica es envasada en un envase impermeable al intercambio gaseoso, siendo el envasado realizado en una atmósfera de gas inerte.
ARP030103710A 2002-10-11 2003-10-10 Composicion farmaceutica estabilizada que comprende una sustancia activa amorfa AR041588A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino

Publications (1)

Publication Number Publication Date
AR041588A1 true AR041588A1 (es) 2005-05-26

Family

ID=32091984

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103710A AR041588A1 (es) 2002-10-11 2003-10-10 Composicion farmaceutica estabilizada que comprende una sustancia activa amorfa

Country Status (21)

Country Link
US (2) US20040077708A1 (es)
EP (1) EP1608362B1 (es)
CN (1) CN100372529C (es)
AR (1) AR041588A1 (es)
AT (2) ATE354362T1 (es)
AU (1) AU2003280361B2 (es)
CY (1) CY1106608T1 (es)
CZ (1) CZ17610U1 (es)
DE (2) DE20321455U1 (es)
DK (2) DK1608362T3 (es)
ES (1) ES2285205T3 (es)
FI (1) FI7617U1 (es)
ME (1) ME00514B (es)
PT (1) PT1608362E (es)
RS (1) RS51819B (es)
RU (1) RU2358727C2 (es)
SI (2) SI21302A (es)
SK (1) SK5233Y1 (es)
TW (1) TWI320709B (es)
UA (1) UA85544C2 (es)
WO (1) WO2004032920A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
JP4739672B2 (ja) 2001-12-21 2011-08-03 ネクター セラピューティクス 湿気のバリアを有するカプセルパッケージ
SK50462005A3 (sk) * 2003-08-05 2005-09-08 Zentiva, A. S. Spôsoby stabilizácie atorvastatínu
PL1727795T3 (pl) 2004-03-17 2012-06-29 Ranbaxy Laboratories Ltd Sposób wytwarzania soli wapniowej atorwastatyny w formie bezpostaciowej
WO2006008091A2 (en) 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
KR20070106680A (ko) * 2004-09-30 2007-11-05 닥터 레디스 레보러터리즈 리미티드 비정질 아토르바스타틴 칼슘
WO2006059224A1 (en) * 2004-12-02 2006-06-08 Warner-Lambert Company Llc Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US20090247603A1 (en) 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1810667A1 (en) * 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
JP2010534644A (ja) * 2007-07-27 2010-11-11 シプラ・リミテッド 医薬組成物およびその製造方法
US20090071855A1 (en) * 2007-09-14 2009-03-19 Bahuguna Sumit Packaging for amorphous statins and compositions thereof
EP2127628A1 (en) * 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Unit dose pack
WO2011077843A1 (ja) 2009-12-25 2011-06-30 沢井製薬株式会社 アトルバスタチン含有被覆製剤
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
CN102525942A (zh) * 2012-01-05 2012-07-04 金陵药业股份有限公司 一种阿托伐他汀钙肠溶微丸及其制备方法
CA3011685C (en) * 2015-02-03 2021-07-20 Kadmon Pharmaceuticals, Llc Stable trientine formulations
US10905113B2 (en) 2015-11-12 2021-02-02 Regents Of The University Of Minnesota Compositions and method for storing liquid biospecimens
EP3184103A1 (en) 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
US11968975B2 (en) 2019-04-30 2024-04-30 Regents Of The University Of Minnesota Compositions and methods for storing liquid biospecimens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2194418B2 (es) * 1971-08-02 1977-01-28 Sada Pietro
DE2625164A1 (de) * 1976-06-04 1977-12-15 Goedecke Ag Fluessige oder halbfeste arzneiformen oder kosmetische zubereitungen
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
AU3761495A (en) * 1994-09-30 1996-04-26 Becton Dickinson & Company Method for forming and packaging iontophoretic drug delivery patches and the like to increase stability and shelf-life
GB9425783D0 (en) * 1994-12-21 1995-02-22 Ethical Pharma Ltd Packaging of patches
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
SG125044A1 (en) * 1996-10-14 2006-09-29 Mitsubishi Gas Chemical Co Oxygen absorption composition
US6155454A (en) * 1997-05-03 2000-12-05 Donald C. George Pill dispenser employing a sealed pill carrier and integrated dispensing plungers
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6375956B1 (en) * 1999-07-22 2002-04-23 Drugtech Corporation Strip pack
EP1296672B2 (en) * 2000-06-09 2018-10-24 LEK Pharmaceuticals d.d. Stable pharmaceutical product and formulation
US6293393B1 (en) * 2000-07-18 2001-09-25 Sdk Co., Inc. Apparatus and methods for packaging and distributing combinations of foods and beverages
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1241110A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs

Also Published As

Publication number Publication date
UA85544C2 (ru) 2009-02-10
CN100372529C (zh) 2008-03-05
SI1608362T1 (sl) 2007-12-31
SK5233Y1 (en) 2009-09-07
DE60312049D1 (de) 2007-04-05
TW200501947A (en) 2005-01-16
FIU20070036U0 (fi) 2007-01-26
SK50062007U1 (en) 2009-03-05
SI21302A (sl) 2004-04-30
RU2358727C2 (ru) 2009-06-20
ATE354362T1 (de) 2007-03-15
CZ17610U1 (cs) 2007-06-18
ES2285205T3 (es) 2007-11-16
EP1608362B1 (en) 2007-02-21
CN1703215A (zh) 2005-11-30
TWI320709B (en) 2010-02-21
WO2004032920A1 (en) 2004-04-22
CY1106608T1 (el) 2012-01-25
FI7617U1 (fi) 2007-09-28
DE60312049T2 (de) 2007-10-04
RS20050273A (en) 2007-06-04
DK200700025U1 (da) 2007-06-08
US20040077708A1 (en) 2004-04-22
AU2003280361A1 (en) 2004-05-04
EP1608362A1 (en) 2005-12-28
ME00514B (me) 2011-10-10
RS51819B (sr) 2011-12-31
PT1608362E (pt) 2007-05-31
US20090012150A1 (en) 2009-01-08
DE20321455U1 (de) 2007-05-24
DK200700025U4 (da) 2008-03-14
DK1608362T3 (da) 2007-05-14
AT10424U1 (de) 2009-03-15
RU2005114485A (ru) 2006-01-27
AU2003280361B2 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
AR041588A1 (es) Composicion farmaceutica estabilizada que comprende una sustancia activa amorfa
ATE486787T1 (de) Portionspackung und halbflüssiges produkt
EP1243524A3 (en) Pharmaceutical kit for oxygen-sensitive drugs
ECSP034868A (es) Cápsulas para inhalación
PE20070320A1 (es) Formulacion que comprende prasugrel como inhibidor de agregacion de plaquetas
AR092919A2 (es) Composicion farmaceutica liquida
DE60309731D1 (de) Injizierbare pharmazeutische suspension in einer phiole mit zwei kammern
DE69913138D1 (de) Stabilisierte zusammensetzung mit nootropen wirkstoffen
CL2010000816A1 (es) Formulacion adecuada para administracion subcutanea que comprende al menos 100 mg/ml de ctlaig, un azucar, y un portador acuoso farmaceuticamente estable; articulo de fabricacion que comprende al menos un recipiente que contiene la formulacion antes mencionada. (divisional solicitud n° 3597-06)
MXPA05012191A (es) Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos.
WO2007040591A3 (en) A ubiquinone composition and a container for its convenient transport and storage
WO2007028046A3 (en) Implant rehydration packages and methods of use
DK1518796T3 (da) Emballeret fødevareprodukt
PT1216057E (pt) Solucao de calcitriol estavel para ser embalada em frascos
CA2303356A1 (en) Active oxygen scavenger compositions and their use in packaging articles
EA200500819A1 (ru) Способы стабилизации аторвастатина
DE50203618D1 (de) Nadelverpackung
ATE315395T1 (de) Pharmazeutische zusammensetzungen, die faropenem natrium und eine diamineacetat verbindung zur verbesserung der magen-darm trakt absorption enthalten
AU2001263892A1 (en) Device for storing and mixing pasty materials
MX9301072A (es) Metodo para reducir el contenido de humedad en empaques hermeticos que contienen dispositivos semiconductores.
EA200801572A1 (ru) Фармацевтическая композиция, содержащая аморфный аторвастатин
HUP9603489A2 (hu) Gyógyszerkészítmény és eljárás előállítására
ATE291421T1 (de) Pharmazeutische, ramipril enthaltende brauseformulierung
AR039720A1 (es) Metodo y envasado para contenedores presurizados
TH132946A (th) ห่อบรรจุ

Legal Events

Date Code Title Description
FB Suspension of granting procedure